Author's response to reviews

Title: Insulin versus oral agents in the management of cystic fibrosis related diabetes: A case based study

Authors:

Gary M Onady (gmonady@pol.net)
Leora J Langdon (LangdonL@childrensdayton.org)

Version: 3 Date: 20 June 2006

Author's response to reviews: see over
June 20, 2006

Editors
BMC Endocrine Diseases

Dear Editors,

This letter is in reference to final revisions for the manuscript “Insulin versus oral agents in the management of cystic fibrosis related diabetes: a case based study” that incorporates the revisions recommended only by Reviewer 3. Feedback on this revised manuscript should be directed toward the corresponding author at the following address.

Gary M. Onady MD, PhD  Phone: (937) 224-3078
Medicine-Pediatrics Program  Fax:  (937) 224-3112
Wright State University  Email: gmonady@pol.net
500 Elizabeth Place
Dayton, OH 45408

The following involves the point-by-point description of the final revisions.

Reviewer 3 noted that hospital and institutional review boards approved the study protocol that was confusing as the abstract noted the study as a retrospective review. I edited text to clarify that the only retrospective patient data used was for baseline data of patients diagnosed with CFRD prior to 1992 that upon approval from the IRBs all patients were followed identically as a prospective study.

Typographical errors identified by Reviewer 3 were corrected as recommended. Abstract Methods and Conclusion sections were proofed and the errors corrected. Likewise, the first paragraph of Background information was reworded. Exclusion criteria described in two separate paragraphs was noted with the entry in the later paragraph eliminated from the Methods section. The Methods section was further corrected as identified by Reviewer 3 as the patients did elect treatment through informed consent.

Once again, I do appreciate the comments regarding revisions recommended by Reviewer 3 and all changes were made as advised. I am truly grateful for all the help received by the editorial staff and reviewers as we now proceed toward final publication.

Sincerely,

Gary M. Onady MD, PhD
Dayton Adult Cystic Fibrosis Program Director